Flatiron Health’s Post

Technology enabled, remote, clinical trial services can significantly improve clinical trial access. Such, decententralised, trial procedures are an important way to improve representation on trials and enhance the quality of data obtained while reducing participant burden. Oncology studies are no different. It's great to see sponsors and sites look to apply learnings and enable these tools to redifine who can participate in cancer clinical trials. Fantastic work published in JAMA Oncology by Bloomberg New Economy, Memorial Sloan Kettering Cancer Center, Bayer | Pharmaceuticals, Amgen Oncology , AstraZeneca FDA Science 37

Delighted to share our latest Bloomberg New Economy #InternationalCancerCoalition study on decentralized trial technologies in oncology. Our research illuminates the path towards patient-centric clinical trials, vital for advancing cancer care equitably. Let's pioneer a new era of inclusivity in research! Read more here #GlobalHealthEquity #GlobalCancerMoonshot https://lnkd.in/e8uusYsA

🔍 How can real-time patient data transform clinical trials? By making trials more adaptable, efficient and customized for better outcomes. Discover how leveraging data is reshaping clinical research and driving faster results—especially in complex areas like oncology. 📊 Read our PharmaTimes Media Ltd article by Samantha Morley and Domantas Gurevicius now to learn more: https://hubs.la/Q02RWYlv0 #ClinicalResearch #DataDriven #OncologyTrials #PrecisionMedicine #PatientOutcomes #ClinicalTrials

This was an insightful read that emphasizes the crucial role of a data-centric, customizable approach in enhancing the efficiency and effectiveness of clinical trials. Check it out here: https://lnkd.in/gkVMkdmE

In a fascinating report by IQVIA Institute for Human Data Science, the authors highlight that the reason oncology timelines are likely increasing is due to trial enrollment and endpoint complexity and number of subjects required. New solutions are needed to address this changing landscape. “This report sets out to characterize the need for clinical trial global diversification by assessing trends in enrollment timelines, trial characteristics, and country utilization over the past five years.” www.npowermedicine.com is uniquely positioned to provide needed infrastructure to oncology clinics to address clinical trial complexity. Get your copy of the report: https://lnkd.in/erWtB-qG #Clinicalresearch #clinicaltrials #oncology

Here’s an interesting article on how using real-time patient data in clinical trials allows for quick adjustments, better resource utilization, and tailored monitoring. #MedicalResearch #ClinicalTrials #HealthcareInnovation #PatientData #DataScience #Pharma #CRO #HealthTech

Have a look (view) and a read on the report from m y colleague Gwyn: Our New Medicines, Novel Insights: Advancing Precision Oncology report, introduced by Dr. Gwyn Bebb, is a testament to our relentless pursuit of better patient outcomes. Our team of experts brings forward clinical trial expertise, regulatory insight, statistical acumen, advanced analytics capabilities and most importantly, patient perspectives. Dive in to explore how we’re pushing the boundaries of precision oncology. 💪 https://lnkd.in/ewvHgfZY #CancerResearch #Oncology #NovelInsights

TriNetX is excited to collaborate with Data Science students from Constructor Academy to delve into factors affecting patient survival in Multiple Myeloma. Leveraging our regulatory-grade TherapyMonitor Multiple Myeloma Real World Data Report, they've crafted a semi-automated Hazard Ratio plotting tool. This innovative solution reveals key patient characteristics influencing survival outcomes. To learn more about TriNetX Oncology, visit TriNetX Oncology GmbH: https://ow.ly/BaMO50QGT8x #MultipleMyeloma #DataScience

Here’s a sneak peek at the first installment of our upcoming video series, “Re-inventing the ‘How’” featuring N-Power’s CEO Mark Lee, MD, PhD and Michael Seiden MD, PhD, N-Power advisor and former President of the US Oncology Network, as they highlight the need for a new integrated model of clinical research and routine care in community oncology to accelerate drug development. Learn more about N-Power: https://lnkd.in/gJESRx3g #oncologyresearch #cancerresearch #realworlddata #HealthcareAI #oncologydrugdevelopment #RWE #Oncology

Really enjoyed my fireside chat with Michael Seiden MD, PhD, former President of the US Oncology Network, where we discussed the need for a new, holistic approach to make clinical research truly accessible for more oncologists and more cancer patients than ever before. Check out this sneak peek preview of our conversation as part of N-Power Medicine, Inc.'s new video series, "Reinventing the How" -- full episode coming next week!